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Background: Anti-HER2 therapies are associated with a risk of increased cardiac toxicity, particularly when part of
anthracycline-containing regimens. We report cardiac safety of pertuzumab, trastuzumab, and chemotherapy in the
neoadjuvant treatment of HER2-positive early breast cancer.
Patients and methods: BERENICE (NCT02132949) is a nonrandomized, phase II, open-label, multicenter, multinational study in
patients with normal cardiac function. In the neoadjuvant period, cohort A patients received four cycles of dose-dense
doxorubicin and cyclophosphamide, then 12 doses of standard paclitaxel plus four standard trastuzumab and pertuzumab
cycles. Cohort B patients received four standard fluorouracil/epirubicin/cyclophosphamide cycles, then four docetaxel cycles
with four standard trastuzumab and pertuzumab cycles. The primary end point was cardiac safety during neoadjuvant
treatment, assessed by the incidence of New York Heart Association class III/IV heart failure and of left ventricular ejection
fraction declines (10 percentage-points from baseline and to a value of<50%). The main efficacy end point was pathologic
complete response (pCR, ypT0/is ypN0). Results are descriptive.
Results: Safety populations were 199 and 198 patients in cohorts A and B, respectively. Three patients [1.5%; 95% confidence
interval (CI) 0.31% to 4.34%] in cohort A experienced four New York Heart Association class III/IV heart failure events. Thirteen
patients (6.5%; 95% CI 3.5% to 10.9%) in cohort A and four (2.0%; 95% CI 0.6% to 5.1%) in cohort B experienced at least one left
ventricular ejection fraction decline. No new safety signals were identified. pCR rates were 61.8% and 60.7% in cohorts A and B,
respectively. The highest pCR rates were in the HER2-enriched PAM50 subtype (75.0% and 73.7%, respectively).
VC The Author(s) 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
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Conclusion: Treatment with pertuzumab, trastuzumab, and common anthracycline-containing regimens for the neoadjuvant
treatment of early breast cancer resulted in cardiac and general safety profiles, and pCR rates, consistent with prior studies with
pertuzumab.
Clinical Trial Information: NCT02132949
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Introduction
HER2 is overexpressed/gene-amplified in15%–20% of breast can-
cers (BC) [1] and associated with poor prognoses. Trastuzumab
plus chemotherapy has progression-free survival (PFS)/overall sur-
vival benefits in HER2-positivemetastatic BC [2]. Pertuzumab, tras-
tuzumab, and docetaxel showed further benefits, with significantly
improved PFS/overall survival versus placebo, trastuzumab, and
docetaxel [3, 4]. Pertuzumab, trastuzumab, and docetaxel is effica-
cious in the neoadjuvant setting, with a 17.8% increase in pathologic
complete response (pCR, ypT0/is ypN0) rates versus trastuzumab
plus docetaxel in NeoSphere [5], and similar benefits in additional
studies [6, 7]. Exploratory PFS and disease-free survival results from
NeoSphere and TRYPHAENA supported pCR benefits [8, 9].
Trastuzumab is associatedwith a risk of cardiac toxicity, particu-
larly when given with anthracyclines. In BCIRG006 (trastuzumab
plus chemotherapy in early BC [EBC]), incidences of congestive
heart failure were 2.0% and 0.4% in the anthracycline- and non-
anthracycline arms, respectively [10]. Higher cardiac event rates
with trastuzumab were also seen in studies of anthracycline-
containing regimens6 trastuzumab [11, 12]. Therefore, cardiac
safety within the context of chemotherapy regimen is an important
consideration.
In CLEOPATRA, there was no increased cardiac risk (heart fail-
ure) with pertuzumab [3, 4]; no additional/long-term cardiotoxic-
ities were associated with combination therapy in NeoSphere [8].
Pertuzumab plus trastuzumab was associated with little additional
toxicity inNeoSphere [5] and TRYPHAENA [6] (mainly increased
incidence, but not severity, of diarrhea, rash, and mucositis); there
was little impact on doses received, dose interruptions/modifica-
tions/discontinuations, or treatment-related mortality [5, 6].
NCCN guidelines recommend pertuzumab-containing regimens
for HER2-positive BC. While pertuzumab plus trastuzumab has
an acceptable safety profile in combination with epirubicin, when
BERENICEwas designed there were no doxorubicin data, and lim-
ited data on pertuzumab, trastuzumab, and paclitaxel in EBC
(GeparSepto assessed paclitaxel/nab-paclitaxel, pertuzumab, and
trastuzumab followed by epirubicin and cyclophosphamide [7]).
The ongoing BERENICE study (NCT02132949) was designed to
evaluate the cardiac safety of two neoadjuvant anthracycline-/tax-
ane-based regimens with pertuzumab and trastuzumab in patients
with locally advanced, inflammatory, or early-stage HER2-positive
BC, and normal cardiac function.We present the primary analysis:
cardiac safety during the neoadjuvant period (clinical cutoff at the
date of last patient’s breast surgery).
Patients and methods
BERENICE is a nonrandomized, phase II, open-label, multicenter,
multinational cardiac safety study across 75 centers/12 countries in full
accordance with Good Clinical Practice guidelines/Declaration of
Helsinki.
All participants provided written informed consent. The protocol and
modifications were approved by independent ethics committees.
Procedures
Eligible patients were investigator-assigned to cohorts (Figure 1). In the
neoadjuvant period, cohort A patients received four q2w cycles of dose-
dense doxorubicin plus cyclophosphamide (ddAC) followed 2weeks
later by 12 qw paclitaxel injections, while cohort B patients received four
q3w cycles of fluorouracil, epirubicin, and cyclophosphamide then four
q3w cycles of docetaxel. In both cohorts, four q3w cycles of trastuzumab
and pertuzumab were started with taxane therapy and continued in the
adjuvant setting (up to 13 cycles to complete 1 year of treatment).
Surgery was scheduled after eight cycles of preoperative therapy. All study
drugs were given intravenously. See supplementary data, available at
Annals of Oncology online, for dose modification, and supplementary
Figure S1, available at Annals of Oncology online, for management of
HER2-targeted treatment based on left ventricular ejection fraction
(LVEF) decreases. Optional granulocyte-colony stimulating factor sup-
port could be given per local practice. Patients could withdraw consent at
any time or be withdrawn by the investigator/sponsor for safety reasons,
if in the patient’s best interests, or for noncompliance with the protocol.
Assessments
Theprimary endpointwas cardiac safety ofneoadjuvant treatment assessedby in-
cidence ofNewYorkHeart Association (NYHA) class III and IV heart failure and
LVEF declines (10 percentage-points from baseline and to a value of <50%
[symptomatic andasymptomatic]) by echocardiographyormultiple-gated acqui-
sition scan. LVEF assessments were conducted at screening/baseline and within
3days before day 1 of cycles 5 and 7 during the neoadjuvant period. Adverse
events (AEs) were assessed throughout the treatment period per National Cancer
Institute–Common Terminology Criteria for Adverse Events (NCI-CTCAE)
V4.0. Safety data are regularly reviewed by the Steering Committee (sponsor rep-
resentatives, investigators, plus an independent cardiology expert). Tumors were
assessed clinically at screening/baseline and at each cycle during neoadjuvant treat-
ment. Patients are also assessed for recurrence at cycles 9, 13, 17, and21during ad-
juvant treatment, and at study completion/termination visits, per local practice.
Secondary end points included general safety during the neoadjuvant period
(including incidence and severity of AEs/serious AEs; laboratory test anomalies)
and all efficacy endpoints. Themain efficacy endpointwas pCR in the breast and
lymph nodes (ypT0/is ypN0; total pCR). pCR assessments were reviewed by an
external pathology expert. Exploratory efficacy end points included local
pathologist-assessed pCR rate and rate by major intrinsic BC subtype. To classify
patients by intrinsic BC subtype, gene expression analyses were carried out by
applying theNanostring nCounter platform.Within the set of genes analyzed, the
panel of genes required to assess the intrinsic BC subtypes as published by Parker
et al was included [13]. The PAM50 subtype prediction to describe themajor in-
trinsic subtypes (HER2-enriched, luminalA, luminalB, andbasal-like)was carried
out using the random-forest-based classifier described by Wilson et al [14].
Further end point details are presented in the supplementary data, available at
Annals ofOncologyonline.
Safety was assessed in all patients who received1 dose of study medi-
cation; pCR, in the intention-to-treat population.
Annals of Oncology Original article
Volume 29 | Issue 3 | 2018 doi:10.1093/annonc/mdx773 | 647
Downloaded from https://academic.oup.com/annonc/article-abstract/29/3/646/4748818
by guest
on 06 April 2018
Statistical methods
No formal sample size calculation/statistical hypothesis testing was perform-
ed. Results were summarized descriptively. Exact Clopper-Pearson 95% CIs
of expected rates (NYHA class III/IV heart failure rate<3% and LVEF de-
cline rate of6%) [5, 6] were used to evaluate cardiac safety.
Results
Population
Patients were enrolled July 2014 to August 2015: 199 were as-
signed to cohort A; 202, to cohort B (supplementary Figure S2,
available at Annals of Oncology online). Intention-to-treat popu-
lations were 199 and 201 patients, respectively; safety popula-
tions, 199 and 198. Clinical cutoff was March 3, 2016, median
(interquartile range) follow-up was 14.5 (13.9–15.5) months in
cohort A and 15.1 (14.5–15.8) months in cohort B.
Demographics/baseline characteristics were similar in each co-
hort (Table 1). Treatment exposure during the neoadjuvant
period is shown in supplementary Table S1, available at Annals of
Oncology online.
Incidence of NYHA class III and IV heart failure
Three patients (1.5%) in cohort A experienced four NYHA class
III/IV heart failure events (Table 2). One patient experienced two
events (one class III and one class IV); due to the close chron-
ology, Steering Committee members considered that these could
represent continuation of one event. All occurred during neoad-
juvant HER2 antibody treatment and all patients discontinued
treatment. Recoveries were recorded for 2/4 events (the patient
with two events recovered from the class IV event only). No pa-
tient in cohort B experienced any events.
Incidence of LVEF declines
Thirteen patients (6.5%) in cohort A and four (2.0%) in cohort B
experienced1 LVEF decline (Table 2). Patients with a decline
should have had treatment withheld and a repeat evaluation
3weeks later. Confirmed declines (2 consecutive declines
during the neoadjuvant period) were observed in two (1.0%) pa-
tients in cohort A and one (0.5%) in cohort B; all during neoadju-
vant HER2-targeted therapy. Declines in the neoadjuvant period
were generally reversible in most patients at the time of analysis,
often with recovery by next assessment.
General safety
The most common AEs (any-grade) during the neoadjuvant
period were nausea, diarrhea, and alopecia (Table 3). The most
common grade 3–4 AEs were blood and lymphatic system dis-
orders, with febrile neutropenia the most common event, fol-
lowed by neutropenia (Table 3). This was in keeping with the
higher proportion of patients who received optional prophylactic
bone marrow support in cohort A. Neutropenia recorded as
“neutrophil count decreased” was reported in 9 patients (4.5%)
in cohort A and 12 (6.1%) in cohort B. No grade 5 AEs were
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FEC q3w ×4
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(A: 60 mg/m2; C: 600 mg/m2)
Paclitaxel qw ×12
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Pertuzumab q3w ×13
(420 mg)
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Pertuzumab q3w ×13
(420 mg)
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Docetaxel q3w ×4
(75 mg/m2 escalating to
100 mg/m2 if no dose-
limiting toxicity)
Pertuzumab q3w ×4
(840 mg→420 mg)
Trastuzumab q3w ×4
(8 mg/kg→6 mg/kg)
Primary tumor
histologically confirmed
as invasive BC and
centrally verified as
HER2-positive by
immunohistochemistry or
in situ hybridization
(HR status was also
centrally assessed)
Primary tumor >2 cm in 
diameter or >5 mm in 
diameter and node-
positive (clinically, on 
imaging, or on 
cytology/histopathology)
Baseline LVEF ≥55%
ECOG performance 
status ≤1
No prior breast or
systemic cancer history
(within 5 years) or
incisional biopsy/excision
of the primary tumor
Figure 1. Study design. BC, breast cancer; ddAC, dose-dense doxorubicin plus cyclophosphamide; ECOG, Eastern Cooperative Oncology
Group; FEC, ﬂuorouracil, epirubicin, and cyclophosphamide; HR, hormone receptor; LVEF, left ventricular ejection fraction; q2w, every 2 weeks;
q3w, every 3 weeks; qw, every week. Only one cohort was opened at a time at any given site, and was deﬁned before any patients were
enrolled at that site. Investigator choice of cohort was based on local/regional practice.
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reported. The most common serious AEs were febrile neutro-
penia and diarrhea. Ten patients (5.1%) in cohort B experienced
grade 3–4 stomatitis (no cases were reported in cohort A). The
most common reason for pertuzumab/trastuzumab discontinu-
ation was ejection fraction decline (including one patient who
discontinued but did not have a confirmed decline).
Efficacy
pCR rates were 61.8% (95% CI 54.7% to 68.6%) and 60.7% (95%
CI 53.6% to 67.5%) in cohorts A and B, respectively, and higher
Table 1. Baseline demographics and tumor characteristics for the
intention-to-treat population
Characteristic Cohort A: Cohort B:
ddACﬁ TPH FECﬁDPH
n5 199 n5 201
Median age, years (IQR) 49.0 (42.0–59.0) 49.0 (42.0–59.0)
Age group
<40 39 (19.6%) 38 (18.9%)
40–65 140 (70.4%) 142 (70.6%)
>65 20 (10.1%) 21 (10.4%)
Female patients 199 (100%) 200 (99.5%)
Estrogen and/or progesterone
receptor status (centrally assessed)
Positive 128 (64.3%) 124 (61.7%)
Negative 65 (32.7%) 75 (37.3%)
Unknown 6 (3.0%) 2 (1.0%)
Primary tumor
TX 0 1 (0.5%)a
T0 1 (0.5%)a 0
T1 18 (9.0%) 12 (6.0%)
T2 138 (69.3%) 130 (64.7%)
T3 33 (16.6%) 45 (22.4%)
T4 9 (4.5%) 13 (6.5%)
Regional lymph nodes
NX 8 (4.0%) 9 (4.5%)
N0 80 (40.2%) 74 (36.8%)
N1 92 (46.2%) 98 (48.8%)
N2 16 (8.0%) 15 (7.5%)
N3 3 (1.5%) 5 (2.5%)
Histologic subtype
Ductal 171 (85.9%) 176 (87.6%)
Lobular 9 (4.5%) 4 (2.0%)
Mucinous 1 (0.5%) 0
Comedo 4 (2.0%) 0
Tubular 2 (1.0%) 0
Not otherwise speciﬁed 14 (7.0%) 19 (9.5%)
Other 8 (4.0%) 8 (4.0%)
Histologic grade n ¼ 198 n ¼ 201
GXb 3 (1.5%) 9 (4.5%)
G1 4 (2.0%) 2 (1.0%)
G2 67 (33.8%) 56 (27.9%)
G3 108 (54.5%) 106 (52.7%)
Unknownc 16 (8.1%) 28 (13.9%)
Intrinsic subtyped n ¼ 199 n ¼ 201
Luminal A 33 (16.6%) 31 (15.4%)
Luminal B 24 (12.1%) 15 (7.5%)
Basal-like 11 (5.5%) 5 (2.5%)
HER2-enriched 80 (40.2%) 95 (47.3%)
Not applicablee 19 (9.5%) 26 (12.9%)
Missingf 32 (16.1%) 29 (14.4%)
Data are n (%) unless stated otherwise.
aPatient was misdiagnosed.
bUnevaluable.
cNot evaluated.
dPatients were classiﬁed by intrinsic BC subtype using gene expression analyses
carried out by applying the Nanostring nCounter platform and the PAM50 subtype
prediction used to describe the major intrinsic subtypes (see supplementary data,
available at Annals of Oncology online).
eThe statistical model applied did not allow categorization into any of the
subgroups.
fTechnical failure (assay failure or failure to extract RNA).
D, docetaxel; ddAC, dose-dense doxorubicin plus cyclophosphamide; FEC,
ﬂuorouracil, epirubicin, and cyclophosphamide; H, trastuzumab; IQR, interquartile
range; P, pertuzumab; T, paclitaxel.
Table 2. Cardiac safety during the neoadjuvant period in the
safety population
Cohort A: Cohort B:
ddACﬁ TPH FECﬁDPH
n5 199 n5 198
NYHA class III/IV heart failure during HER2 antibody
treatment in the neoadjuvant perioda
Patients with at least one
NYHA class III/IV heart
failure
3 (1.5%; 95% CI
0.31% to 4.34%)
0 (95% CI
0% to 1.85%)
Number of events 4 0
NCI-CTCAE grade, patients
Grade 3 1 (0.5%) 0
Grade 4 2 (1.0%) 0
NYHA classiﬁcation, events
Class III 3 (1.5%) 0
Class IV 1 (0.5%) 0
LVEF declines during the neoadjuvant perioda,b
Patients with at least one
LVEF decline
13 (6.5%; 95% CI
3.5% to 10.9%)
4 (2.0%; 95% CI
0.6% to 5.1%)
Number of LVEF declines,
events
19 5
Onset before neoadjuvant
HER2-targeted therapy
(cycles 1–4), patients
0 1 (0.5%)
Onset during neoadjuvant
HER2-targeted therapy
(cycles 5–8), patients
13 (6.5%) 3 (1.5%)
Patients with at least one
conﬁrmed LVEF declinec
2 (1.0%; 95% CI
0.1% to 3.6%)
1 (0.5%; 95% CI
0% to 2.8%)
95% CIs were calculated with the use of the Clopper-Pearson method.
aIncludes events with onset from the ﬁrst dose of pertuzumab or trastuzumab be-
fore surgery through the day before the ﬁrst dose of any study drug after surgery. If
a patient withdrew without entering the adjuvant period, the table includes all AEs
with onset from ﬁrst dose of pertuzumab or trastuzumab through 42 days after last
dose of any study drug or on the day of target surgery, whichever is later. Multiple
occurrences of the same events in one individual are counted only once in the
patient frequency counts.
bMeasured by ECHO/MUGA.
cConﬁrmed LVEF declines are deﬁned as at least two consecutive readings of
declines in LVEF, and single declines are deﬁned as only one reading of declines
(no consecutive readings) in LVEF.
CI, conﬁdence interval; D, docetaxel; ddAC, dose-dense doxorubicin plus cyclo-
phosphamide; FEC, ﬂuorouracil, epirubicin, and cyclophosphamide; H, trastuzumab;
LVEF, left ventricular ejection fraction; NCI-CTCAE, National Cancer Institute—
Common Terminology Criteria for Adverse Events; NYHA, New York Heart
Association, P, pertuzumab; T, paclitaxel.
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in hormone receptor (HR)-negative versus HR-positive disease
(Figure 2A).
Local pathologist-assessed rates were 63.8% (95% CI 56.7% to
70.5%) in cohort A and 61.2% (95% CI 54.1% to 68.0%) in co-
hort B, including five patients in cohort A and four in cohort B
with nodal stage NX. Of these, five patients did not have nodes as-
sessed at surgery but were considered by the local pathologist to
have achieved pCR.
Most patients had HER2-enriched BC (Table 1), and the high-
est pCR rate was observed in this group (75.0% in cohort A and
73.7% in cohort B; Figure 2B). The pCR rate was similar in lu-
minal A and B groups across both cohorts (Figure 2B).
Discussion
The primary objective of BERENICE was to evaluate cardiac
safety of trastuzumab, pertuzumab, and eight cycles of neoadju-
vant chemotherapy (four anthracycline-based followed by four of
dual HER2-targeted therapy plus taxane).
Overall incidence of NYHA class III/IV heart failure during neo-
adjuvant treatment was low and consistent with TRYPHAENA [6].
Notably, BERENICE included a longer neoadjuvant period (eight
versus six chemotherapy cycles) [6].
General safety was consistent with anticipated toxicity profiles
of these regimens. Incidence of diarrhea associated with the
taxane period was lower in cohort A; however, other reports have
shown no difference in rates across taxanes when given with per-
tuzumab and trastuzumab [15]. Diarrhea was mostly low-grade,
and only one patient (cohort B), discontinued pertuzumab/tras-
tuzumab as a result. pCR rates were high in both cohorts and con-
sistent with previous reports [5, 6]. Previous studies have
reported pCR rates of 22%–64% for combinations of HER2-
targeted therapy plus chemotherapy [5–7, 16–28]. The high rate
in HR-negative disease was consistent with data on trastuzumab
plus pertuzumab6 taxanes [29]. Lower rates in HR-positive dis-
ease were consistent with the lower rates observed in luminal A
and B subtypes. The high pCR rate in the HER2-enriched subtype
was consistent with data demonstrating that this subtype could
identify patients who would most likely benefit from dual HER2-
blockade [30]. Our distributions of relevant intrinsic subtypes
(HER2-enriched and luminal A) are also broadly reflective of
those reported in a HER2-positive population [31]. Patients will
be followed for long-term efficacy outcomes.
BERENICE has limitations due to its design. As it is non-
randomized, the chemotherapy backbone’s contribution to the
data cannot be assessed. No control arm also means that the im-
pact of pertuzumab alone on the safety/efficacy of the regimen
cannot be assessed.
The safety/efficacy of pertuzumab plus trastuzumab and
chemotherapy versus placebo plus trastuzumab and chemo-
therapy in the adjuvant setting was recently reported in the
APHINITY trial, where pertuzumab significantly improved in-
vasive disease-free survival with no new safety signals being
identified [32]. BERENICE, KRISTINE [16], and PEONY
(NCT02586025) will evaluate pertuzumab plus trastuzumab
treatment continuing from the neoadjuvant into the adjuvant
setting. These trials will assess 1 year of dual HER2-targeted
antibody therapy in EBC, spanning the neoadjuvant and/or
adjuvant periods.
Conclusion
Treatment with pertuzumab, trastuzumab, and common
anthracycline-containing chemotherapy regimens for the neoad-
juvant treatment of EBC resulted in cardiac and general safety
profiles, and pCR rates, consistent with prior pertuzumab stud-
ies. This is the first study to investigate ddAC followed by pacli-
taxel with pertuzumab and trastuzumab in the neoadjuvant
setting. The safety profiles and high pCR rates in both cohorts
support the use of pertuzumab and trastuzumab with a taxane
following doxorubicin- or epirubicin-based chemotherapy in the
neoadjuvant setting.
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Table 3. General safety during the neoadjuvant period in the safety
population
Patients with at least one: Cohort A:
ddACﬁ TPH
Cohort B:
FECﬁDPH
n5 199 n5 198
AE (any grade) 197 (99.0%) 198 (100%)
Grade 3–4 AE 99 (49.7%) 108 (54.5%)
Serious AE 45 (22.6%) 52 (26.3%)
AE leading to pertuzumab or
trastuzumab discontinuation
10 (5.0%) 4 (2.0%)
Most common grade 3–4 AEs
(2% of patients)
Febrile neutropenia 14 (7.0%) 34 (17.2%)
Neutropenia 24 (12.1%) 17 (8.6%)
Diarrhea 6 (3.0%) 20 (10.1%)
Neutrophil count decreased 9 (4.5%) 12 (6.1%)
Fatigue 2 (1.0%) 9 (4.5%)
Anemia 6 (3.0%) 5 (2.5%)
Stomatitis 0 10 (5.1%)
White blood cell count decreased 8 (4.0%) 4 (2.0%)
Vomiting 2 (1.0%) 8 (4.0%)
Mucosal inﬂammation 2 (1.0%) 7 (3.5%)
Nausea 5 (2.5%) 4 (2.0%)
Hypokalemia 4 (2.0%) 3 (1.5%)
Neutropenic sepsis 0 6 (3.0%)
Alanine aminotransferase increased 4 (2.0%) 2 (1.0%)
Bone marrow failure 1 (0.5%) 4 (2.0%)
Device-related infection 4 (2.0%) 1 (0.5%)
Neuropathy peripheral 4 (2.0%) 0
AE, adverse event; D, docetaxel; ddAC, dose-dense doxorubicin plus
cyclophosphamide; FEC, ﬂuorouracil, epirubicin, and cyclophosphamide; H,
trastuzumab; P, pertuzumab; T, paclitaxel.
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Figure 2. pCR (ypT0/is ypN0) (A) in the intention-to-treat (ITT) population and (B) by intrinsic breast cancer subtype.a D, docetaxel; ddAC,
dose-dense doxorubicin plus cyclophosphamide; FEC, ﬂuorouracil, epirubicin, and cyclophosphamide; H, trastuzumab; HR, hormone recep-
tor; P, pertuzumab; pCR, pathologic complete response; T, paclitaxel. Six patients in cohort A and two in cohort B had missing central HR
assessments. aPatients were classiﬁed by intrinsic BC subtype using gene expression analyses carried out by applying the Nanostring
nCounter platform and the PAM50 subtype prediction used to describe the major intrinsic subtypes (see supplementary data, available at
Annals of Oncology online). bThe statistical model applied did not allow categorization into any of the subgroups. cTechnical failure (assay
failure or failure to extract RNA).
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